Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk

Clinical and Experimental Nephrology

Volumn 19, Issue 6, 2015, Pages 1054-1061

  Dey, Ritwik ^a   Rajappa, Medha ^a   Parameswaran, Sreejith ^a   Revathy, G ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Atherogenic dyslipidemia; Chronic kidney disease; Framingham risk score; Magnesium

Indexed keywords

CALCIUM; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PHOSPHORUS; TRIACYLGLYCEROL; UREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL; LIPOPROTEIN;

ADULT; AGE; ALCOHOLISM; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LIPID BLOOD LEVEL; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHOSPHATE BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; AGED; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; INDIA; MAGNESIUM DEFICIENCY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; URINE;

ADULT; AGED; ATHEROSCLEROSIS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; INDIA; LIPOPROTEINS; MAGNESIUM DEFICIENCY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84951906528     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1097-z     Document Type: Article

References (36)

1. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–83.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
3. Covic AC. Magnesium in chronic kidney disease-more than just phosphate binding. Europ Nephrol. 2010;4:28–36.
4. Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the atherosclerosis risk in communities Study. Arch Intern Med. 1999;159:2151–9.
5. He K. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. 2006;113:1675–82.
6. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The atherosclerosis risk in communities (ARIC) study. Am Heart J. 1998;136:480–90.
7. Altura BM, Altura BT. Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res. 1995;41:347–59.
8. Rosanoff A, Seelig MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr. 2004;23:501S–5S.
9. Gupta BK, Glicklich D, Tellis VA. Magnesium repletion therapy improved lipid metabolism in hypomagnesemic renal transplant recipients: a pilot study. Transplantation. 1999;67:1485–7.
10. Reinhart K, Baker WL, Siv ML-W. Beyond the guidelines: new and novel agents for the prevention of atrial fibrillation after cardiothoracic surgery. J Cardiovasc Pharmacol Ther. 2011;16:5–13.
11. Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5:i52–61.
12. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol. 2008;40:1075–82.
13. Reffelmann T, Ittermann T, Dörr M, Völzke H, Reinthaler M, Petersmann A, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011;219:280–4.
14. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. J Clin Epidemiol. 1995;48:927–40.
15. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res. 2007;20:237–44.
16. Nassiri AA, Hakemi MS. Serum magnesium level and cardiovascular disease in dialysis patients. Iran J Kidney Dis. 2013;7:2–4.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
19. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Circulation. 2004;109:433–8.
20. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.
21. Hajhosseiny R, Khavandi K, Goldsmith DJ. Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract. 2013;67:14–31.
22. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.
23. Spiegel DM. Magnesium in chronic kidney disease: unanswered questions. Blood Purif. 2011;31:172–6.
24. Khatami MR, Mirchi E, Khazaeipour Z, Abdollahi A, Jahanmardi A. Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. Iran J Kidney Dis. 2013;7:47–52.
25. Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, et al. Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res Off Organ Int Soc Dev Res Magnes. 2004;17:102–8.
26. Maier JA, Malpuech-Brugère C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta. 2004;1689:13–21.
27. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011;13:843–7.
28. Sontia B, Montezano ACI, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension. 2008;51:915–21.
29. Tejero-Taldo MI, Kramer JH, Mak IT, Komarov AM, Weglicki WB. The nerve-heart connection in the pro-oxidant response to Mg-deficiency. Heart Fail Rev. 2006;11:35–44.
30. Baradaran A, Nasri H. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Indian J Nephrol. 2004;14:46.
31. Ansari MR, Maheshwari N, Shaikh MA, Laghari MS, Lal K, Ahmed K, et al. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis. Saudi J Kidney Dis Transplant. 2012;23:21.
32. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, Altura BM. Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA. 1990;87:1840–4.
33. Soltani N, Keshavarz M, Dehpour AR. Effect of oral magnesium sulfate administration on blood pressure and lipid profile in streptozocin diabetic rat. Eur J Pharmacol. 2007;560:201–5.
34. Nasri H. Re: association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. Iran J Kidney Dis. 2013;7:241–2.
35. Bo S, Pisu E. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol. 2008;19:50–6.
36. Rayssiguier Y. Magnesium, lipids and vascular diseases. Experimental evidence in animal models. Magnesium. 1986;5:182–90.